Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
60°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
127.29
+0.41 (+0.32%)
Streaming Delayed Price
Updated: 2:44 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Merck to Present at the Barclays 2023 Global Healthcare Conference
March 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
March 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
March 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
March 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
March 02, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
March 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
Is Amazon a Blue Chip Stock?
February 28, 2023
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat.
Via
MarketBeat
What is the Best Dividend ETF?
February 28, 2023
Dividend ETFs may take a lot of the hassle out of picking stocks, and this one fund has even manged to beat the market over the last decade.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
February 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
February 24, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk
February 22, 2023
Via
ACCESSWIRE
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
February 22, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
February 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
February 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
February 17, 2023
From
Merck & Co., Inc.
Via
Business Wire
Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
February 16, 2023
Animal health company Zoetis is up 7.99% in the past week, after topping fourth-quarter views. Analysts see double-digit EPS growth in 2023 and 2024.
Via
MarketBeat
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
February 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
February 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat Week in Review – 2/6 - 2/10
February 11, 2023
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Interest Rates
Should Investors Buy or Sell the Vaccinex Patent News?
February 07, 2023
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
February 07, 2023
Despite beating analysts’ expectations on the top and bottom lines, MRK stock fell after earnings. This article analyzes if investors should jump in
Via
MarketBeat
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
February 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
February 02, 2023
From
Merck & Co., Inc.
Via
Business Wire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
January 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
January 26, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
January 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
January 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
January 25, 2023
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
Via
MarketBeat
Merck Announces Second-Quarter 2023 Dividend
January 24, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.